Related Experiment Video
Updated: Jan 31, 2026

Advanced 3D Liver Models for In vitro Genotoxicity Testing Following Long-Term Nanomaterial Exposure
Published on: June 5, 2020
Interaction of biologically relevant proteins with ZnO nanomaterials: A confounding factor for in vitro toxicity
Emilie Da Silva1, Yahia Kembouche2, Ulla Tegner2
1The National Research Center for the Working Environment, Lersø Parkallé 105, Copenhagen, Denmark; Department of Environmental Engineering, Technical University of Denmark, Bygningstorvet 115, Kgs. Lyngby, Denmark.
Abstract:
The results of in vitro toxicological studies for manufactured nanomaterials (MNs) are often contradictory and not reproducible. Interference of the MNs with assays has been suggested. However, understanding for which materials and how these artefacts occur remains a major challenge. This study investigated interactions between two well-characterized ZnO MNs (NM-110 and NM-111) and lactate dehydrogenase (LDH), and two interleukins (IL-6 and IL-8). Particles (10 to 640 μg/mL) and proteins were incubated for up to 24 h in routine in vitro assays test conditions. LDH activity (ODLDH), but not interleukins concentrations, decreased sharply in a dose-dependent manner within an hour after exposure (ODLDH < 60% of ODref for both MNs at 10 μg/mL). A Freundlich adsorption isotherm was successfully applied, indicating multilayer adsorption of LDH. ZnO MNs and LDH had neutral to slightly negative surface charges in dispersion, precluding electrostatic attachment. Particle sedimentation was not a limiting factor. Fast dissolution of ZnO MNs was shown and Zn2+ could play a role in the ODLDH drop. To summarize, ZnO MNs quickly reduced ODLDH due to concentration-dependent adsorption and LDH inhibition by interaction with dissolved Zn. The control of particle interference in toxicological in vitro assays should become mandatory to avoid misleading interpretation of results.
Related Concept Videos
Factors Affecting Protein-Drug Binding: Drug Interactions
Displacement interactions can have varying outcomes, ranging from toxicity to virtually...
Factors Affecting Drug Biotransformation: Biological
Species differences: Variations in enzyme systems across species can cause disparities in drug metabolism. For instance, humans may metabolize certain drugs faster than rodents, altering therapeutic effects.
Strain differences: Genetic variations within a species can result in differing enzyme activity, impacting drug response and toxicity. For example, some mouse strains may...
Confounding in Epidemiological Studies
Factors Affecting Protein-Drug Binding: Protein-Related Factors
The physicochemical properties of a drug play a significant role in its ability to bind to proteins. Lipophilic drugs, which dissolve in fats, oils, and lipids, can be...
Factors Affecting Protein-Drug Binding: Drug-Related Factors
One crucial factor in drug-protein binding is the drug's lipophilicity or its affinity for fat. More lipophilic drugs tend to have higher binding extents. For example, highly lipophilic drugs like cloxacillin exhibit substantial protein binding, with as much as 95% of the drug binding to proteins. In...
Factors Affecting Protein-Drug Binding: Patient-Related Factors
Age stands as a key determinant in protein-drug binding. Neonates, characterized by low albumin content, experience heightened concentrations of unbound drugs such as phenytoin and...

